Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 19.48 is 235% above its 5-year average of 5.82, near the high end of its 5-year range (0.75–19.48).
As of the fiscal period ended Tuesday, June 30, 2026. 261.21% above its 12-month average of 5.39.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 19.48.
QUICK RATIO (ACID-TEST)
19.48
QUICK RATIO (ACID-TEST) AVG TTM
5.39
QUICK RATIO (ACID-TEST) AVG 3Y
3.91
QUICK RATIO (ACID-TEST) AVG 5Y
5.82
QUICK RATIO (ACID-TEST) AVG 10Y
5.10
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+261.21%
CURRENT VS 3Y AVG
+397.90%
CURRENT VS 5Y AVG
+234.87%
CURRENT VS 10Y AVG
+281.72%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.16
median of 722 covered companies
CURRENT VS SECTOR MEDIAN
+517.40%
vs the sector median at left
Indaptus Therapeutics, Inc.
Market Cap
$281.97M
Quick Ratio (Acid-Test)
19.48
TTM Avg
5.39
3Y Avg
3.91
5Y Avg
5.82
Market Cap
$283.83M
Quick Ratio (Acid-Test)
31.35
TTM Avg
25.02
3Y Avg
20.04
5Y Avg
16.05
Market Cap
$288.40M
Quick Ratio (Acid-Test)
6.40
TTM Avg
6.41
3Y Avg
5.95
5Y Avg
4.92
Market Cap
$289.63M
Quick Ratio (Acid-Test)
4.69
TTM Avg
11.27
3Y Avg
11.27
5Y Avg
11.27
Market Cap
$288.98M
Quick Ratio (Acid-Test)
8.80
TTM Avg
4.55
3Y Avg
3.67
5Y Avg
2.92
Market Cap
$280.29M
Quick Ratio (Acid-Test)
2.80
TTM Avg
2.74
3Y Avg
2.22
5Y Avg
2.48
Market Cap
$278.55M
Quick Ratio (Acid-Test)
4.85
TTM Avg
6.69
3Y Avg
6.56
5Y Avg
6.64
Market Cap
$274.62M
Quick Ratio (Acid-Test)
9.24
TTM Avg
7.84
3Y Avg
8.19
5Y Avg
10.90
Market Cap
$295.12M
Quick Ratio (Acid-Test)
4.70
TTM Avg
5.10
3Y Avg
7.75
5Y Avg
8.34
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | $281.97M | 19.48 | 5.39 | 3.91 | 5.82 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.83M | 31.35 | 25.02 | 20.04 | 16.05 |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.40M | 6.40 | 6.41 | 5.95 | 4.92 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $289.63M | 4.69 | 11.27 | 11.27 | 11.27 |
| Standard BioTools Inc. (LAB)vs › | $288.98M | 8.80 | 4.55 | 3.67 | 2.92 |
| Aurora Cannabis Inc. (ACB)vs › | $280.29M | 2.80 | 2.74 | 2.22 | 2.48 |
| Fate Therapeutics, Inc. (FATE)vs › | $278.55M | 4.85 | 6.69 | 6.56 | 6.64 |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $274.62M | 9.24 | 7.84 | 8.19 | 10.90 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $295.12M | 4.70 | 5.10 | 7.75 | 8.34 |
| Benitec Biopharma Inc. (BNTC)vs › | $300.36M | 34.00 | 44.34 | 25.02 | 19.51 |
Quick Ratio
19.48
Excludes inventory
Current Ratio
19.48
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 19.48 |
| 2026-03-31 | 2.34 |
| 2025-12-31 | 1.51 |
| 2025-09-30 | 2.88 |
| 2025-06-30 | 0.75 |
| 2025-03-31 | 1.90 |
| 2024-12-31 | 1.95 |
| 2024-09-30 | 3.42 |
| 2024-06-30 | 3.88 |
| 2024-03-31 | 6.70 |
| 2023-12-31 | 5.05 |
| 2023-09-30 | 7.12 |
| 2023-06-30 | 9.45 |
| 2023-03-31 | 12.15 |
| 2022-12-31 | 7.94 |
| 2022-09-30 | 10.27 |
| 2022-06-30 | 9.18 |
| 2022-03-31 | 10.03 |
| 2021-12-31 | 8.77 |
| 2021-09-30 | 7.59 |
| 2021-06-30 | 3.45 |
| 2021-03-31 | 0.86 |
| 2020-12-31 | 0.86 |
| 2020-09-30 | 3.89 |
| 2020-06-30 | 3.45 |
| 2020-03-31 | 2.64 |
| 2019-12-31 | 1.65 |
| 2019-09-30 | 1.57 |
| 2019-06-30 | 2.46 |
| 2019-03-31 | 3.26 |
| 2018-12-31 | 5.69 |
| 2018-09-30 | 9.21 |
| 2018-06-30 | 7.41 |
| 2018-03-31 | 8.24 |
| 2017-12-31 | 9.80 |
| 2017-09-30 | 19.90 |
| 2017-06-30 | 6.39 |
| 2017-03-30 | 0.00 |
| 2015-12-31 | 25.20 |
| 2015-09-30 | 17.75 |
| 2015-06-30 | 3.02 |
| 2015-03-30 | 0.00 |
